elzovantinib   Click here for help

GtoPdb Ligand ID: 11869

Synonyms: compound 5 [WO2019023417A1] | CSF1R-IN-2 | TPX-0022 | TPX002
Compound class: Synthetic organic
Comment: Elzovantinib (TPX-0022) is a MET tyrosine kinase inhibitor that targets the SRC and CSF1R pathways in cancers [1]. It has demonstrated activity in patients with MET-driven gastric cancer in Phase 1 clinical trial.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 121.57
Molecular weight 409.17
XLogP 2.89
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCN1Cc2c(ccc(c2C#N)F)O[C@@H](C)CNC(=O)c2c3nc1ccn3nc2N
Isomeric SMILES CCN1Cc2c(ccc(c2C#N)F)O[C@H](CNC(=O)c2c3nc1ccn3nc2N)C
InChI InChI=1S/C20H20FN7O2/c1-3-27-10-13-12(8-22)14(21)4-5-15(13)30-11(2)9-24-20(29)17-18(23)26-28-7-6-16(27)25-19(17)28/h4-7,11H,3,9-10H2,1-2H3,(H2,23,26)(H,24,29)/t11-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Turning Point Therapeutics have advanced TPX-0022 into clinical evaluation. TPX-0022 was granted orphan drug designation by the FDA (in June 2021) as a treatment for patients with gastric cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03993873 Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Phase 1 Interventional Turning Point Therapeutics, Inc.